Hypertrophic Cardiomyopathy Challenging Questions

Rick A. Nishimura M.D. M.A.C.C.

Judd and Mary Morris Leighton Professor

Mayo Clinic Rochester



No disclosures




- ? Genetics ?
- ? Myectomy?
- ? Natural history ?
- ? ICD ?



Question 1: what about genetics and HCM?






Old Definition:
Severe hypertrophy
of the myocardium
in the absence of a
known etiology



"Essentially, HCM is always a genetic disorder..."


Marian and Roberts Circ 1995: 92: 1336-1347




Over 16 defective sarcomeric genes with over 500 different mutations

2 nonsarcomeric genes (PRKAG2 and LAMP2)






Diagnosis of HCM - Year 2020




Early age Spontaneous LVH



Massive LVH
Reverse curve septum
Sudden death

Later age Triggered: HTN, AS




Mild LVH Sigmoid septum CHF, AF

- Genetics Clinical implications
 - Screen all first degree relatives
 - Adults every 5 years
 - Adolescents every year (especially athletes)
 - Obtain family history of HCM or sudden death



- Question 1: what about genetics and HCM?
- Question 2 : what about different types of myectomy?






LVO obstruction


Caused by SAM
Present in 2/3 pts with HCM
Major cause of symptoms
Ischemia
Diastolic dysfunction

Mitral regurgitation

LAP 45 mmHg








Relieve obstruction Septal myectomy

Transaortic approach
Operative risk < 1%
Results


Gradient < 10 mmHg No residual MR Complete relief sx



LAP 12 mmHg




Septal Myectomy – 10 yr F/U Symptomatic Improvement




It is clear that surgical myectomy will result in marked <u>long-lasting</u> symptomatic improvement in over 90% of patients with severe symptoms and obstruction




Septal Myectomy – Long term outcome





Apical HCM


Diffuse symmetric T wave inversions
Disease of diastole
Abnormal effective operative compliance









Novel "apical myectomy"
Remove massive myocardium
Through apical approach











Increase LV volume Improve effective operative compliance

Improve symptoms of dyspnea





Adverse natural history apical HCM

Apical ischemia


Apical aneurysm + mid obstruction




Once development of apical aneurysm


- More symptoms
- Higher risk VT
- Increased risk embolic events






May need contrast enhancement to identify apical aneurysms





Another type of "myectomy"


- Transapical approach
- Resect midventricular obstruction
- Resect apical aneurysm




- Question 1: what about genetics and HCM?
- Question 2: what about different types of myectomy?
- Question 3 and 4: what about natural history and sudden death?












Initial studies at referral centers High annual mortality (4-7%/yr) Majority due to sudden death



Low Annual Mortality Overall



Most Common Cause Sudden
Death In Young



✓ Unpredictable - years go by

✓ AICD can be lifesaving

✓ Can we predict who is at risk?



Vol. 58, No. 25, 2011 ISSN 0735-1097/\$36.00 dot:10.1016/j.jacc.2011.06.011

PRACTICE GUIDELINE

2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy

A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines

Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons

WRITING COMMITTEE MEMBERS


Bernard J. Gersh, MB, ChB, DPhil, FACC, FAHA, Co-Chair*†;
Barry J. Maron, MD, FACC, Co-Chair*†; Robert O. Bonow, MD, MACC, FAHA‡;
Joseph A. Dearani, MD, FACC§||; Michael A. Fifer, MD, FACC, FAHA*†;
Mark S. Link, MD, FACC, FHRS*¶; Srihari S. Naidu, MD, FACC, FSCAI*#;
Rick A. Nishimura, MD, FACC, FAHA†; Steve R. Ommen, MD, FACC, FAHA†;
Harry Rakowski, MD, FACC, FASE†**; Christine E. Seidman, MD, FAHA†;
Jeffrey A. Towbin, MD, FACC, FAHA††; James E. Udelson, MD, FACC, FASNC‡‡§§;
Clyde W. Yancy, MD, FACC, FAHA|||



Risk Factors – Literature


- Out-of-hospital arrest
- Sustained VT
- Family history sudden death HCM
- Massive hypertrophy
- Syncope
- NSVT on Holter
- TMET VT or drop BP





AMERICAN COLLEGE of CARDIOLOGY

ACC/AHA Guidelines



This is the best that we had.. But positive predictive accuracy < 15%




20-25% incidence Inappropriate shocks (younger active population of HCM)



Sudden death in HCM pts What's New?

- ✓ Age is important
- ✓ MRI with gadolinium
- ✓ Risk scores






Sudden death in HCM pts Age is important

- √ 76 y/o man with syncope after
 getting up in the middle of the night
- ✓ 23 y/o college student who suddenly passes out in class



Myocyte Disarray









Gadolinium Enhancement Defects on MRI

1293 HCM pts - F/U 3.3 yrs

Incidence SCD events




% Late Gadolinium Enhancement



Chan et al: Circulation 2014:130:484-495

HCM Risk-SCD Calculator



HCM Risk Score

Low risk 5 yr < 4%

No ICD

ESC guidelines European Ht J 2014 Intermediate risk 5 yr 4-6%

ICD may be considered


High risk 5 yr > 6%

ICD should be considered

AMERICAN

COLLEGE of CARDIOLOGY

Patients who had appropriate firings from ICD vs ESC risk score



Maron et al: AJC 2015



Patients who had appropriate firings from ICD vs ESC risk score



22% of patients who had appropriate ICD firings were "low risk"

Young Severe LVH Young Strong FH



Mayo Data

Putting it altogether Consideration of AICD in HCM

FH sudden death

1° relative Sudden death < 40 y/o Sudden death with HCM

Massive LVH

- > 30 mm
- > 25 mm*
- *young age
 - *MRI GE

Syncope

Unexplained Young Recent

All others: Calculate ESC risk score
Consider AICD if 5 yr risk > 6%



Putting it altogether Consideration of AICD in HCM


This needs to be a shared decision making process involving the needs and preferences of the patient and resources available



Hypertrophic Cardiomyopathy


- ? Genetics ?
- ? Myectomy?
- ? Natural history ?
- ? ICD ?






AMERICAN COLLEGE of CARDIOLOGY

48 y/o man with HCM- Asymptomatic
No FH HCM or sudden death
On lopressor 200 mg per day
Septal thickness 3.2 cm
LVO gradient 90 mmHg
Normal coronaries – 2 mm septal





What would you do now?

- 1. Implant ICD
- 2. Add disopyramide
- 3. Septal ablation
- 4. Septal myectomy





AMERICAN COLLEGE of CARDIOLOGY



HCM Related Death or Adverse Clinical Events in 70 Patients with LV Apical Aneurysms

